• Gyre Therapeutics Chief Operating Officer Weiguo Ye sold 28,680 shares on May 14-15 at weighted average prices of $6.91 and $6.65.
• The sales followed option exercises for the same number of shares at $0.75.
• Ye ended May 15 with 700,000 shares of common stock beneficially owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-021889), on May 18, 2026, and is solely responsible for the information contained therein.